<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393718</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1700</org_study_id>
    <nct_id>NCT00393718</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic
      control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after
      24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24
      weeks followed by a 28 week extension period, in total 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose AUC After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
    <description>Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose AUC After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
    <description>Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
    <description>Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
    <description>Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
    <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
    <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight After 24 Weeks of Treatment</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight After 52 Weeks of Treatment</measure>
    <time_frame>after 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic Episodes</measure>
    <time_frame>over 52 weeks of treatment</time_frame>
    <description>Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glibenclamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glibenclamide 1.25-2.5 mg + liraglutide placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>0.9 mg/day. Injected s.c. (under the skin) once daily.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
    <description>1.25-2.5 mg tablet. Given orally once or twice daily.</description>
    <arm_group_label>Glibenclamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>liraglutide placebo. Injected s.c. (under the skin) once daily.</description>
    <arm_group_label>Glibenclamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>glibenclamide placebo. Given orally once or twice daily.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight
             weeks

          -  HbA1c greater than or equal to 7.0% and less than 10.0%

          -  BMI (Body Mass Index) less than 35 kg/m2

        Exclusion Criteria:

          -  Treatment with insulin within the last 12 weeks

          -  Treatment with any drug that could interfere with the glucose level

          -  Any serious medical condition

          -  Females who are pregnant, have intention of becoming pregnant or are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.</citation>
    <PMID>20199137</PMID>
  </results_reference>
  <results_reference>
    <citation>Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012 Aug 20;3(4):388-95. doi: 10.1111/j.2040-1124.2012.00193.x.</citation>
    <PMID>24843595</PMID>
  </results_reference>
  <results_reference>
    <citation>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.</citation>
    <PMID>23010561</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2006</study_first_posted>
  <results_first_submitted>February 23, 2010</results_first_submitted>
  <results_first_submitted_qc>February 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2010</results_first_posted>
  <disposition_first_submitted>October 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 26, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2009</disposition_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>75 sites in Japan.</recruitment_details>
      <pre_assignment_details>Subjects included in the study were patients with type 2 diabetes treated with diet therapy only or diet therapy and one OAD (Oral Anti-Diabetic Drug). Subjects on OAD therapy discontinued their current treatment during the run-in period (Weeks 4-6 before dosing). A total of 411 subjects were randomised, 11 subjects were not exposed to study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide</title>
          <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
        </group>
        <group group_id="P2">
          <title>Glibenclamide</title>
          <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycaemia</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed measurement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide</title>
          <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
        </group>
        <group group_id="B2">
          <title>Glibenclamide</title>
          <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="268"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70- years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="10.4"/>
                    <measurement group_id="B2" value="58.5" spread="10.4"/>
                    <measurement group_id="B3" value="58.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.90" spread="3.69"/>
                    <measurement group_id="B2" value="24.62" spread="3.84"/>
                    <measurement group_id="B3" value="24.81" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.19" spread="12.61"/>
                    <measurement group_id="B2" value="65.43" spread="12.89"/>
                    <measurement group_id="B3" value="65.94" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>Number of years since diagnosis of diabetes</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.13" spread="6.68"/>
                    <measurement group_id="B2" value="8.48" spread="6.84"/>
                    <measurement group_id="B3" value="8.25" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Glycosylated Haemoglobin</description>
          <units>percentage of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.27" spread="0.75"/>
                    <measurement group_id="B2" value="8.28" spread="0.78"/>
                    <measurement group_id="B3" value="8.28" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment</title>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>percentage of total haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99" spread="0.07"/>
                    <measurement group_id="O2" value="7.50" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANOVA model included HbA1C at baseline as a covariate and treatment group and pre-trial treatment as fixed effects.
Hypothesis for non-inferiority:
H0: μ0.9 - μG ≥ 0.4, H1: μ0.9 - μG &lt; 0.4,
Hypothesis for superiority:
H0: μ0.9 - μG ≥ 0.0, H1: μ0.9 - μG &lt; 0.0, where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively. When non-inferiority was confirmed, superiority was evaluated based on the closed testing procedure.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion: Upper limit of confidence interval of mean difference(= Liraglutide - Glibenclamide) is less than 0.4%. Superiority criterion: Upper limit of confidence interval of mean difference(= Liraglutide - Glibenclamide) is less than 0.0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is for the null hypothesis for superiority. A significance level of a one-sided 2.5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment</title>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>percentage of total haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.08"/>
                    <measurement group_id="O2" value="7.80" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose After 24 Weeks of Treatment</title>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose After 24 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.2" spread="1.9"/>
                    <measurement group_id="O2" value="150.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed based on an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate. The following null hypothesis (H0) was statistically tested against the alternative hypothesis (H1). H0: μ0.9 = μG, H1: μ0.9 ≠ μG where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A significance level of a two-sided 5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-12.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.2</ci_lower_limit>
            <ci_upper_limit>-7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose After 52 Weeks of Treatment</title>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose After 52 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.8" spread="2.4"/>
                    <measurement group_id="O2" value="157.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.6</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Glucose AUC After 24 Weeks of Treatment</title>
        <description>Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment</description>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glucose AUC After 24 Weeks of Treatment</title>
          <description>Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL *h</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557.54" spread="9.53"/>
                    <measurement group_id="O2" value="670.60" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed based on an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate. The following null hypothesis (H0) was statistically tested against the alternative hypothesis (H1). H0: μ0.9 = μG, H1: μ0.9 ≠ μG where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A significance level of a two-sided 5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-93.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-119.61</ci_lower_limit>
            <ci_upper_limit>-66.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Glucose AUC After 52 Weeks of Treatment</title>
        <description>Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment</description>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glucose AUC After 52 Weeks of Treatment</title>
          <description>Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL *h</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.66" spread="11.18"/>
                    <measurement group_id="O2" value="683.17" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-74.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-105.75</ci_lower_limit>
            <ci_upper_limit>-43.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</title>
        <description>Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</title>
          <description>Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.98" spread="2.61"/>
                    <measurement group_id="O2" value="173.61" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed based on an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate. The following null hypothesis (H0) was statistically tested against the alternative hypothesis (H1). H0: μ0.9 = μG, H1: μ0.9 ≠ μG where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A significance level of a two-sided 5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-17.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.00</ci_lower_limit>
            <ci_upper_limit>-10.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</title>
        <description>Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</title>
          <description>Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.39" spread="3.22"/>
                    <measurement group_id="O2" value="184.60" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-17.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.32</ci_lower_limit>
            <ci_upper_limit>-8.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</title>
        <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment</title>
          <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.69" spread="2.83"/>
                    <measurement group_id="O2" value="79.66" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed based on an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate. The following null hypothesis (H0) was statistically tested against the alternative hypothesis (H1). H0: μ0.9 = μG, H1: μ0.9 ≠ μG where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A significance level of a two-sided 5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-19.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.99</ci_lower_limit>
            <ci_upper_limit>-11.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</title>
        <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment</title>
          <description>Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.</description>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.56" spread="2.96"/>
                    <measurement group_id="O2" value="76.59" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-13.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.46</ci_lower_limit>
            <ci_upper_limit>-4.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight After 24 Weeks of Treatment</title>
        <time_frame>after 24 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight After 24 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.06" spread="0.15"/>
                    <measurement group_id="O2" value="65.97" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed based on an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate. The following null hypothesis (H0) was statistically tested against the alternative hypothesis (H1). H0: μ0.9 = μG, H1: μ0.9 ≠ μG where μ0.9 and μG are population mean after 24-week treatment for liraglutide 0.9 mg/day and glibenclamide, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A significance level of a two-sided 5% was used for statistical hypothesis testing.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>-1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight After 52 Weeks of Treatment</title>
        <time_frame>after 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight After 52 Weeks of Treatment</title>
          <population>Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.30" spread="0.19"/>
                    <measurement group_id="O2" value="66.01" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval for the mean difference (liraglutide – glibenclamide) was calculated under an ANOVA model with treatment group and pre-trial treatment as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean</param_type>
            <param_value>-1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycaemic Episodes</title>
        <description>Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
        <time_frame>over 52 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) consists of all subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide</title>
            <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Episodes</title>
          <description>Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
          <population>Full Analysis Set (FAS) consists of all subjects who received at least one dose of study drug.</population>
          <units>number of events per year of exposure</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All hypoglycaemic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.694"/>
                    <measurement group_id="O2" value="3.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.187"/>
                    <measurement group_id="O2" value="1.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.507"/>
                    <measurement group_id="O2" value="2.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The relative risk for 'All hypoglycaemic episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The relative risk for 'Minor episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The relative risk for 'Symptoms only' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected in a time span over 52 weeks.</time_frame>
      <desc>The safety analysis population consists of all subjects exposed to study drug (Full Analysis Set, FAS).</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>Liraglutide 0.9 mg + glibenclamide placebo</description>
        </group>
        <group group_id="E2">
          <title>Glibenclamide</title>
          <description>Glibenclamide 1.25–2.5 mg + liraglutide placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Ventriculoperitoneal shunt malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colon polypectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="268"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="268"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="268"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="183" subjects_affected="100" subjects_at_risk="268"/>
                <counts group_id="E2" events="94" subjects_affected="57" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="48" subjects_affected="25" subjects_at_risk="268"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk acknowledges the Investigator’s right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

